M&A

Merck KGaA to acquire Rapid Micro Biosystems in $0.75-per-share all-cash deal

The deal will bring Rapid Micro Biosystems’ Growth Direct platform, which automates microbial quality control, into Merck KGaA’s Life Science business

  • By IPP Bureau | November 19, 2026
Merck KGaA, Germany, has agreed to acquire Rapid Micro Biosystems in an all-cash deal valued at $0.75 per share, marking a major development for the life sciences technology company.
 
Under a definitive agreement announced by Rapid Micro Biosystems, Merck KGaA will acquire all outstanding shares of the company, subject to the terms and conditions of the agreement.
 
The deal will bring Rapid Micro Biosystems’ Growth Direct platform, which automates microbial quality control, into Merck KGaA’s Life Science business. The platform is used by leading pharmaceutical manufacturers to streamline quality-control processes and accelerate the release of healthcare products.
 
The acquisition builds on an 18-month partnership between the two companies, which have focused on innovation and modernising quality-control workflows across the pharmaceutical industry.
 
"Over the past 18 months, we have built a strong partnership with Merck KGaA, Darmstadt, Germany, centered on a shared commitment to innovation and helping customers modernize and automate their quality-control workflows,” said Robert Spignesi, President and CEO of Rapid Micro Biosystems. 
 
“Rapid Micro has established the Growth Direct platform as the leading solution for automating microbial quality control, with most of the world's top pharmaceutical manufacturers as customers. We are confident that joining the Life Science business of Merck KGaA, Darmstadt, Germany will significantly expand the Growth Direct platform’s reach and more fully serve our combined global customer base."
 
For Merck KGaA, the acquisition is expected to strengthen its quality-control offering by adding greater automation to a critical stage of pharmaceutical manufacturing, where speed, reliability and regulatory compliance are essential.
 
“Quality control is essential to the reliable manufacture of medicines,” said Paolo Carli, Head of Advanced Solutions for the Life Science business of Merck KGaA, Darmstadt, Germany. 
 
“Our customers need reliable results faster, more efficient quality-control workflows and robust data integrity to support regulatory compliance. Rapid Micro Biosystems will strengthen our ability to meet those needs, building on our existing offering and bringing greater automation to a critical step in pharmaceutical manufacturing.”

Upcoming E-conference

Other Related stories

Startup

Digitization

Collaborative models are practical way to build capability in biologics: Manoj Kumar Panicker, Cytiva and Dr. Sanjib Banerjee, Veeda Lifesciences
Collaborative models are practical way to build capability in biologics: Manoj Kumar Panicker, Cytiva and Dr. Sanjib Banerjee, Veeda Lifesciences
(L-R) Manoj Kumar Panicker, General Manager, South Asia, Cytiva and Dr. Sanjib Banerjee, Chief Operating Officer (Biopharma Services), Veeda Lifesciences.